Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Sponsor: Jemincare
Summary
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
Official title: A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect of JMKX001899 on the QTc Interval in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2024-07-10
Completion Date
2025-02-27
Last Updated
2024-06-25
Healthy Volunteers
Yes
Conditions
Interventions
JMKX001899
Participants will receive JMKX001899 500mg tablet, orally once on Day 1
JMKX001899
Participants will receive JMKX001899 750mg tablet, orally once on Day 1
JMKX001899
Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
Placebo
Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1